Phase Forward Senior Professional Barry Burnstead Honored with Membership Lifetime Award
This year's DIA European EuroMeeting Conference programme will address a broad range of topics, including the challenges of the revised Pharmaceutical Legislation, which is the driving force for review of all aspects of regulatory achievement. The Legislation also brings many opportunities for cooperative associations among stakeholders, who will work together to successfully challenge the R&D paradigms of the past and revitalise them for the future. The objective is to develop safe, effective and quality-assured medicines that ensure public health.
Phase Forward Senior Professional Earns Lifetime Award
Phase Forward's Barry Burnstead will be honoured during the DIA Distinguished Career and Outstanding Services Award ceremony on Monday, March 6th with a lifetime membership award in acknowledgement of his active participation in the DIA.
As part of this year's conference, Barry Burnstead will be co-chair of the Data Management track (Track 12) and will chair the session titled Managing Clinical Trial and Pharmacovigilance Safety Data (Tuesday, March 7, 14:00). This session describes how the worlds of clinical data management and pharmacovigilance interface in significant ways. Serious adverse events attract equal attention from all stakeholders. Global strategies and processes need to address this common interest. Furthermore, the advent of electronic capture of clinical data from trials adds a new dynamic, impacting procedure for validating and reporting. Common interest exists in coding activities of shared data with contrasting requirements driving different solutions. However, the industry is prepared to seek out new solutions and this session looks at how two companies sponsoring trials address these challenges and provides insight into how conflicting coding requirements can be addressed.
Phase Forward Showcases Clinical Data Management and Drug Safety Solutions
Attendees are invited to visit the Phase Forward and Lincoln Technologies exhibit to learn more about the company's clinical data management and drug safety solutions, including the industry leading InForm™ EDC solution, the new Clinical Trials Signal Detection (CTSD™) product, and the WebVDME™ pharmacovigilance signal detection and signal management product.
Learn more about Phase Forward and Lincoln Technologies at Stand: 108–110
For media inquiries, please contact Kevin Payne of De Facto Communications at +44 (0)20 7861 3023.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.